<DOC>
	<DOCNO>NCT00684307</DOCNO>
	<brief_summary>The main purpose study provide dose-guiding information assess safety tolerability 4 different dose regimen extended-release ( ER ) formulation AZD0837 compare well-controlled , dose-adjusted Vitamin-K antagonist ( VKA ) ( aim international normalize ratio ( INR ) 2.0 3.0 ) patient non-valvular atrial fibrillation ( AF ) one additional risk factor stroke .</brief_summary>
	<brief_title>Prevention Stroke Systemic Embolic Events Patients With Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<criteria>Nonvalvular AF ( NVAF ) verify least two ECGs last year separate least one week . Previous cerebral ischemic attack ( stroke TIA , &gt; 30 day prior randomization ) Previous systemic embolism . Symptomatic congestive heart failure ( CHF ) Impaired leave ventricular systolic function Diabetes mellitus Hypertension require antihypertensive treatment . AF secondary reversible disorder , eg hyperthyroidism , drug pulmonary embolism Known contraindication VKA treatment Presence valvular heart disease , mechanical heart valve , active endocarditis , leave ventricular aneurysm thrombus , atrial myxoma condition AF require chronic anticoagulation treatment Conditions associate increase risk major bleed example : history intracranial bleeding , history bleed gastrointestinal disorder major surgical procedure trauma two week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Anticoagulant Treatment</keyword>
	<keyword>Risk Factors For Stroke</keyword>
</DOC>